Table 3.
Characteristics in the patients with or without neoadjuvant therapy
| Patients with neoadjuvant therapy (n = 36) | Patients without neoadjuvant therapy (n = 42) | |||||
|---|---|---|---|---|---|---|
| Factors | Low TB (n = 25) | High TB (n = 11) | p value | Low TB (n = 29) | High TB (n = 13) | p value |
| Age (y.o.) | 70 (49–84) | 69 (39–77) | 0.520 | 67 (40–87) | 69 (44–78) | > 0.999 |
| Gender (Male / Female) | 13 / 12 | 9 / 2 | 0.091 | 18 / 11 | 7 / 6 | 0.616 |
| Type of Neoadjuvant therapy | ||||||
| Chemotherapy | 17 (68.0%) | 8 (72.7%) | 0.777 | – | – | – |
| Chemoradiotherapy | 8 (32.0%) | 3 (27.3%) | ||||
| PTPE | 4 (16.0%) | 2 (18.2%) | 0.871 | 8 (27.6%) | 4 (30.8%) | 0.833 |
| Initial tumor marker | ||||||
| CEA (ng/mL) | 3.7 (1.3–14.6) | 3.9 (0.9–16.3) | 0.685 | 2.9 (0.6–38.4) | 2.6 (0.7–28.0) | 0.936 |
| CA19–9 (U/mL) | 61.5 (1.0–7898) | 140.3 (1.0–1325) | 0.435 | 87.5 (7.0–1115.7) | 65.1 (1.0–9278) | 0.872 |
| Preoperative tumor marker | ||||||
| CEA (ng/mL) | 2.6 (0.9–9.6) | 3.6 (1.1–24.4) | 0.151 | 3.0 (0.7–32.2) | 2.6 (0.5–32.3) | 0.788 |
| CA19–9 (U/mL) | 33.2 (1.0–11,659) | 151.3 (1.0–1158) | 0.086 | 67.3 (13.7–977.2) | 65.1 (1.0–9278) | 0.936 |
| Type of liver resectiona | 0.114 | |||||
| No liver resection | 0 | 0 | 5 (17.2%) | 0 | ||
| S1,5,6,7,8 | 9 (36.0%) | 3 (27.3%) | 10 (34.5%) | 5 (38.5%) | ||
| S1,4,5,6,7,8 | 1 (4.0%) | 1 (9.1%) | 2 (6.9%) | 3 (23.1%) | ||
| S1,2,3,4 | 9 (36.0%) | 6 (54.5%) | 7 (24.1%) | 4 (30.8%) | ||
| S1,2,3,4,5,8 | 3 (12.0%) | 1 (9.1%) | 0 | 1 (7.7%) | ||
| Others | 3 (12.0%) | 0 | 5 (17.2%) | 0 | ||
| HPD | 0 | 1 (9.1%) | 0.126 | 3 (10.3%) | 0 | 0.229 |
| Combined HA and/or PV resection | 12 (48.0%) | 10 (90.9%) | 0.015 | 11 (37.9%) | 6 (46.2%) | 0.616 |
| Operation time (min) | 625 (383–965) | 672 (422–972) | 0.261 | 597 (403–1030) | 610 (435–746) | 0.914 |
| Blood loss (ml) | 2212 (505–6916) | 2170 (1459–6012) | 0.612 | 1964 (166–9907) | 1830 (587–3870) | 0.727 |
| Histological type | ||||||
| G1, 2 / G3 | 25 / 0 (0%) | 6 / 5 (45.5%) | < 0.001 | 26 / 3 (10.3%) | 12 / 1 (7.7%) | 0.787 |
| UICC 8th | ||||||
| pT: T0–3 / T4 | 19 / 6 (24.0%) | 4 / 7 (63.6%) | 0.023 | 23 / 6 (20.7%) | 8 / 5 (38.5%) | 0.226 |
| pN: N0 / N1–2 | 17 / 8 (32.0%) | 3 / 8 (72.7%) | 0.023 | 16 /13 (44.8%) | 4 / 9 (69.2%) | 0.143 |
| M: M0 / M1a | 25 / 0 (0%) | 8 / 3 (27.3%) | 0.006 | 28 / 1 (3.4%) | 11 / 2 (15.4%) | 0.165 |
| Residual tumor status | ||||||
| R0 / R1 / R2 (M1 / margin positive) | 17 / 6 / 2 (0 / 2) | 6 / 1 / 4 (3 / 1) | 0.092 | 21 / 5 / 3 (1 / 2) | 9 / 2 / 2 (2 / 0) | 0.895 |
| Postoperative hospital stay (days) | 45 (13–161) | 37 (17–136) | 0.308 | 49 (25–117) | 56 (18–325) | 0.374 |
| Postoperative complication ≥ grade IIIb | 13 (52.0%) | 6 (54.5%) | 0.888 | 9 (31.0%) | 4 (30.8%) | 0.986 |
| Postoperative chemotherapy | 19 (76.0%) | 9 (81.8%) | 0.699 | 18 (62.1%) | 10 (76.9%) | 0.345 |
Patients in high TB groups had a significantly higher rate of combined vascular resection in patients received neoadjuvant therapy. In patients without preoperative therapy, there were no significant differences in preoperative and operative factors. Among 36 patients with neoadjuvant therapy, the rates of G3, T4, N1–2, and M1 in high TB group were significantly higher than those in low TB. As for postoperative factors, there were no differences between two groups in both patients with and without neoadjuvant therapy
aM1 include 3 patients with intrahepatic metastasis. b Clavien-Dindo classification